|1.||Shimada, Kaoru: 1 article (11/2002)|
|2.||Ueda, Satoko: 1 article (11/2002)|
|3.||Suga, Osamu: 1 article (11/2002)|
|4.||Kanai, Yoshihito: 1 article (11/2002)|
|5.||Nagahisa, Atsushi: 1 article (11/2002)|
|6.||Fujiwara, Yoshiko: 1 article (11/2002)|
|7.||Tsuchiya, Megumi: 1 article (11/2002)|
|8.||Mizutani, Mayumi: 1 article (11/2002)|
|9.||Watson, John W: 1 article (11/2002)|
|10.||Callahan, Michael J: 1 article (07/2002)|
10/01/2001 - "A phase II, double-blind, randomized study was performed to assess the safety and efficacy of ezlopitant for the control of cisplatin-induced emesis. "
11/01/2002 - "In addition, repeated subcutaneous injection of ezlopitant significantly inhibited delayed retching and vomiting responses that occurred in ferrets treated with the lower dose of cisplatin (5 mg/kg, i.p.). "
11/01/2002 - "In ferrets, ezlopitant, either orally (0.03-3 mg/kg) or subcutaneously (0.3-3 mg/kg), prevented acute retching and vomiting responses induced by intraperitoneal injection of cisplatin (10 mg/kg). "
11/01/2002 - "Anti-emetic activity of the novel nonpeptide tachykinin NK1 receptor antagonist ezlopitant (CJ-11,974) against acute and delayed cisplatin-induced emesis in the ferret."
|3.||Irritable Bowel Syndrome (Syndrome, Irritable Bowel)
|4.||Dehydration (Water Stress)
12/01/2001 - "The alkene arises as a direct product of metabolism of ezlopitant rather than through dehydration of the benzyl alcohol. "
12/01/2001 - "Intramolecular deuterium isotope effects of the dehydrogenation reaction for tri- and tetradeuterated analogs were very low (1.13-1.15) for both CYP3A4 and CYP2D6, whereas intramolecular isotope effects for the chemical dehydration of correspondingly deuterated ezlopitant benzyl alcohol (CJ-12,764) were 3.8 to 5.9. "
|2.||Benzyl Alcohol (Benzenemethanol)
|3.||Cytochrome P-450 CYP2D6 (CYP2D6)